1 / 10

Hormone Receptor (HR)-positive market / Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Market

Hormone receptors are proteins that receive hormone signals and cue the cancer cells to grow. If breast cancer cells get signals from the hormone estrogen that could promote tumor growth, it is known as estrogen receptor-positive (ER ) breast cancer.<br>

DelveInsight
Download Presentation

Hormone Receptor (HR)-positive market / Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hormone Receptor (HR)- positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Market Insights, Epidemiology and Market Forecast–2028

  2. If cancerous cells get signals from the hormone progesterone that could promote growth, then known as progesterone receptor-positive (PR+) breast cancer. Breast cancer that is ER-positive or PR-positive falls under the category of hormone receptor- positive (HR+) breast cancer. HR-positive/HER2-negative Breast Cancer HR-positive cancer is usually treated with hormone therapies or a combination of hormone therapy with targeted therapy to help stop tumor growth first. There are more number of cases for breast cancer in women observed in comparison to the men. Hormone receptors are proteins that receive hormone signals and cue the cancer cells to grow. If breast cancer cells get signals from the hormone estrogen that could promote tumor growth, it is known as estrogen receptor-positive (ER+) breast cancer. • DelveInsight © 2019 | All rights reserved

  3. HR-positive/ HER2-negative Breast Cancer Epidemiology Among the various subtypes of the disease, HR+/HER2- occupies the maximum patient pool, followed by the number of those with Triple negative and HR-positive/HER2 negative. The United States show higher Breast Cancer incidence with 266,120 cases in 2017 and Japan accounts for the second highest breast cancer incident cases with 89,100. The total incident population Breast Cancer in the 7MM is expected to grow at CAGR of 0.83%during study period [2017–2028]. Among the EU-5 countries, Germany ranked first with 71,585 cases whereas Spain has the least number of breast cancer incident cases. • DelveInsight © 2019 | All rights reserved

  4. HR-positive/ HER2-negative Breast Cancer Market Among the EU-5 countries, Germany had the highest HR-positive/HER2-negative breast cancer market sizein 2017 that accounts for 25.51% of the total market. The United States had the HR-positive/HER2-negative breast cancer highest market size in 2017that accounts for 83.96% of the total market. HR-positive/ HER2-negative Breast market size in the 7MM* countries was observed to be USD 5,237.2 million in 2017. HR-positive/HER2-negative breast cancer market size was found to be USD 4216.4 million in 2017. • DelveInsight © 2019 | All rights reserved {*7MM includes - USA, EU-5 (Germany, Spain, Italy, France and UK), Japan}

  5. HR-positive/ HER2-negative Breast Cancer Market Outllook HR-positive/ HER2-negative Breast Cancer Emerging Drugs and Companies 02 01 03 04 Company- Immunomedics Drug- IMMU-132 Company- Jiangsu HengRui Medicine Drug- SHR6390 Company- OdonateTherapeutics Drug- TESETAXEL Company- Roche Group Drug- RG7440 • DelveInsight © 2019 | All rights reserved

  6. Complete Information For complete information on Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Market Insights, Epidemiology and Market Forecast–2028 please click the link below CLICK HERE OR Write Us At  info@delveinsight.com • DelveInsight © 2019 | All rights reserved

  7. About DelveInsight MISSION VISION ABOUT DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process. To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long-term relationship with them. • DelveInsight © 2019 | All rights reserved

  8. Service Offerings By Delveinsight OPPORTUNITY ASSESSMENT FORECASTING PIPELINE REPORT STORE COMPETITIVE ANALYSIS CONSULTING MARKET INTELLIGENCE PHARMDELVE • DelveInsight © 2019 | All rights reserved

  9. Contact Us blog/delveInsight/ info@delveinsight.com +91-11-4568 9769 twitter/delveInsight LinkedIn/delveInsight www.delveinsight.com • DelveInsight © 2019 | All rights reserved

  10. THANK YOU

More Related